WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Disease modeling

Studying disease models gives an understanding of how a disease develops, offering insight into potential treatment approaches and responses to drug candidates

Current industry methods

Current in vitro disease models do not fully represent the scope and symptoms of a disease.

Most models are short-term (up to seven days) and limited to a single immortalized cell type, making them unable to functionally mimic the properties of an organ.

Advancements with PhysioMimix®

PhysioMimix allows you to create complex and physiologically relevant models that accurately express the disease phenotype.

More complete disease models generate clinically translatable data to prevent unexpected results in the clinic.

Multi-well plates

Non-alcoholic steatohepatitis


Liver disease is a major health problem worldwide accounting for approximately two million deaths annually. A proportion of deaths due to Non-Alcoholic Fatty Liver Disease (NAFLD) and its more advanced stage, Non-Alcoholic Steatohepatitis (NASH) are preventable.

With anti-NASH therapeutics failing to pass clinical trials, a new preclinical test is required to improve human efficacy predictions. Our NAFLD/NASH application provides a pre-clinical in vitro model using human tissue to fully replicate this critical liver disease phenotype.

Learn more
LC12 plates

Hepatitis B


Hepatitis B (HBV) is a human-specific hepatotropic virus that increases the risk of terminal liver disease. The specificity of the disease reduces the number of suitable models available for research and therapeutic development.

CN Bio has developed perfused human hepatocytes cultured in 3D as a preclinical tool to study the HBV life cycle and novel therapeutics in the human liver.

Learn more
LC12 plate, tube and pipette

COVID-19


The lung is extremely vulnerable to infection and injury due to constant exposure to inhaled particles and pathogens in the environment. Respiratory diseases are a leading cause of death globally which has been exacerbated by the COVID-19 pandemic.

With only 3% of new pulmonary therapeutics reaching the market, there is a need for innovative preclinical models which can accurately mimic the human lung and predict responses to infection and novel therapeutics.

Learn more

Jump to area of interest

Non-alcoholic steatohepatitis
Hepatitis B
COVID-19

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023